RxDoctor Payments Data

Matthew Messina, PA

Physician Assistant · Wellington, FLNPI 1861151961

Payments from drug & device makers

$2,157in general payments, 2019–2025

Across 92 payments — averaging $23.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$559
  • Antares Pharma, Inc.$379
  • Endo USA, Inc.$288
  • Endo Pharmaceuticals Inc.$263
  • Astellas Pharma US Inc$173
  • Novartis$106
  • plus $388 from 10 others

What the payments were for

  • Food & beverage$2,08997%
  • Education$683%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,157 in reported general payments places this provider in the 75th percentile of 8,062 physician assistant providers in Florida.

See all physician assistant providers in Florida

Medicare billing

Part B allowed, 2024
$8,273
Medicare patients
63
Services billed
687

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron64$52,134
GemtesaVibegron28$36,305
XyostedTestosterone Enanthate16$10,003
Dutasteride328$9,246
Tamsulosin Hcl385$6,030
Alfuzosin Hcl ErAlfuzosin Hcl262$5,330
Testosterone Cypionate100$3,742
Silodosin39$3,584
Potassium Citrate ErPotassium Citrate19$2,678
Testosterone17$2,326
Methenamine Hippurate33$1,865
Finasteride89$1,269
Cephalexin300$1,006
Bethanechol Chloride12$985
Solifenacin Succinate15$931

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$173$52,13464 claims
Antares Pharma, Inc.Xyosted$379$10,00316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,062 physician assistant providers in Florida.

Other physician assistant in Wellington

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →